Navigation Links
Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
Date:11/19/2012

d the development of a high performance sixty plus member supply chain organization.  Prior to Animas, Mr. Sunday held manufacturing and supply chain positions at Kulicke & Soffa Industries, Efector Inc., Porter Instrument Company, and Ethicon Inc.  Mr. Sunday has a deep knowledge of manufacturing operations and FDA and ISO regulatory standards.  He received his B.S. degree in Industrial and Management Engineering from Widener University and an MBA from LaSalle University.

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and tr
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
2. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
3. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
4. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
5. Echo Therapeutics Announces Third Quarter 2012 Financial Results
6. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
7. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Novelos Therapeutics Closes $2 Million Private Placement
10. US Allows Two Key Patents for Silence Therapeutics
11. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Ill. and LONDON, Sept. 23 Following today’s announcements ... the European Medicines Agency (EMA) for rosiglitazone in the ... Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s commitment ... and to the millions of people living with type ...
... Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two ... of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®,-- ... Performance in Key Safety and Efficacy... -- ABBOTT PARK, Ill., Sept. 23 ... ...
Cached Medicine Technology:Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 2Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 3Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 5Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 6Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 7Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 8Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 9
(Date:7/28/2014)... divide unless there is enough oxygen present to support ... types circumvent this rule. Researchers at The Johns Hopkins ... cells, warning signals, enabling cancers to continue to divide ... the researchers found that lysosomes the cell,s protein ... also uncovered new evidence that certain drugs can halt ...
(Date:7/28/2014)... Parker Waichman LLP, a personal injury law firm ... heroes of 9/11 are never forgotten, comments that the September ... According to a VCF message dated July 3, ... or before October 12, 2012 must file a Registration Form ... who were allegedly injured by the toxic dust cloud that ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
(Date:7/28/2014)... Utah (PRWEB) July 28, 2014 Bariatric ... and drinks, announced that it will be introducing three ... of products this summer. The additional flavors include: , ... pure taste-free protein , Inspire Pomegranate Razz Berry -­ ... flavor of soft-serve vanilla cone , Bariatric Eating's ...
(Date:7/28/2014)... one of two dopamine-producing regions in the brain was ... isoflurane or propofol. In the August issue of ... report that rats anesthetized with continuous doses of either ... up in response to electrical stimulation delivered to the ... major dopamine-releasing area, the substantia nigra, did not induce ...
Breaking Medicine News(10 mins):Health News:Cell's recycling center implicated in division decisions 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2
... By Steven Reinberg HealthDay Reporter , ... have prostate cancer that,s considered "intermediate risk," radiation plus ... a new study finds. This combination of treatments, ... prostate cancer or advanced disease, the researchers said. Men ...
... cardiologists are prone to misinterpreting electrocardiograms when using ... heart defects that could make exercising perilous, according ... School of Medicine and Lucile Packard Children,s Hospital. ... acumen of pediatric cardiologists from several health-care institutions ...
... HealthDay Reporter , WEDNESDAY, July 13 (HealthDay News) -- ... infection can significantly reduce the chance they will develop the ... is an extremely exciting finding for the field of HIV ... a University of Washington associate professor of global health. ...
... , WEDNESDAY, July 13 (HealthDay News) -- Rural workers are often ... loved one and their jobs, researchers report. According to ... University of New Hampshire, people who work in rural communities have ... lost pay or lost jobs and caring for themselves or a ...
... control, growing wildly and breaking all the rules of orderly ... is a balance between a cancer cell,s revved-up metabolism and ... depends on a hyperactive metabolism to fuel its rapid growth, ... reactive oxygen species (ROS) generated by such high metabolic demand. ...
... WEDNESDAY, July 13 (HealthDay News) -- Wearing flip-flops and baseball ... warns. "Most skin cancers occur on the parts of ... Rebecca Tung, director of the dermatology division at Loyola University ... release. "The problem with flip-flops and baseball caps is ...
Cached Medicine News:Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 2Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 3Health News:Pediatric cardiologists not always accurate in interpreting ECG results for young athletes 2Health News:Pediatric cardiologists not always accurate in interpreting ECG results for young athletes 3Health News:Drugs May Prevent HIV Spread Among Heterosexuals 2Health News:Drugs May Prevent HIV Spread Among Heterosexuals 3Health News:Rural Workers Often Lack Access to Sick Leave 2Health News:Taking out a cancer's co-dependency 2Health News:Taking out a cancer's co-dependency 3Health News:Flip-Flops, Baseball Caps May Raise Risk of Skin Cancer 2
Transcranial vascular DWL doppler....
Transcranil vascular DWL doppler....
... is a powerful automated system capable of ... from 6 user-programmable test protocols to begin ... Any tests not included in the comprehensive ... handled using the Doppler, PVR and PPG ...
The CD Horizon M10 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
Medicine Products: